These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21291575)

  • 1. [New antithrombotics for atrial fibrillation].
    Verheugt F
    Ned Tijdschr Geneeskd; 2011; 155():A2143. PubMed ID: 21291575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
    Martí-Fàbregas J; Mateo J
    Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antithrombotics for atrial fibrillation.
    Bereznicki LR; Peterson GM
    Cardiovasc Ther; 2010 Oct; 28(5):278-86. PubMed ID: 20645985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants in development.
    Weitz JI
    Thromb Haemost; 2010 Jan; 103(1):62-70. PubMed ID: 20062934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke prevention in atrial fibrillation.
    Verheugt FW
    Neth J Med; 2006 Feb; 64(2):31-3. PubMed ID: 16517985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants to prevent stroke in atrial fibrillation.
    Verheugt FW
    Nat Rev Cardiol; 2010 Mar; 7(3):149-54. PubMed ID: 20179722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL; Hwang JM; Moser LR
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anticoagulants for the prevention of stroke in atrial fibrillation.
    Höchtl T; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):47-53. PubMed ID: 21883447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meeting the unmet needs in anticoagulant therapy.
    Weitz JI
    Eur J Haematol Suppl; 2010 Jul; (72):1-28. PubMed ID: 20553560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Limitations of anticoagulant therapy].
    Martí-Fàbregas J; Delgado-Mederos R; Mateo J
    Neurologia; 2012 Mar; 27 Suppl 1():27-32. PubMed ID: 22682207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.
    Dobrev D; Goette A; Ravens U
    Cardiovasc Ther; 2009; 27(4):223-5. PubMed ID: 19903184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments].
    Gersh BJ; Freedman JE; Granger CB
    Rev Esp Cardiol; 2011 Apr; 64(4):260-8. PubMed ID: 21411211
    [No Abstract]   [Full Text] [Related]  

  • 20. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.